| Name | Title | Contact Details |
|---|
Imprimis Pharmaceuticals is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at affordable prices. We are pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high quality, proprietary formulations that are supported by the clinical experience of physicians and their patients. We are focused on ophthalmology and urology drug therapies; however we also sell other formulations outside of our core ophthalmology and urology therapeutic areas. All of our innovative drug formulations are born from the clinical experience of physician prescribers and pharmacist formulators. We believe our unique business model provides us with the opportunity to address unmet patient needs while delivering safe, near-term and affordable medical solutions to Americans. We have made tremendous progress since the launch of our ophthalmology business and our Go Dropless™ educational campaign in April 2014. Our ophthalmology business is disrupting the billion dollar eye drop market as physicians are adopting Dropless Therapy™ for their patients. We recently announced the availability of our LessDrops™ proprietary topical combination eye drops for post LASIK and other ocular surgeries. During first quarter 2015, we launched our urology business, entering the multi-billion dollar interstitial cystitis (IC) market. In connection with our urology launch, we will commercialize our patented Hep-Lido-A formulation and promote the Defeat IC™ educational campaign focused on medical practitioners and the estimated ten million women and men in the U.S. chronically affected by IC and PBS. We are committed to customer relations, highest quality standards, accessible innovation and solving the unmet needs in the markets we serve. We are delivering on the promise of our unique model and look forward to continuing to serve the needs of our customers with additional novel drug therapies in our product portfolio, and in turn grow our business. Our hope is that through the success of our business we will reduce healthcare costs and provide Americans access to high quality, novel and previously unavailable medicines.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.
The Harvard Drug Group is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A change for the Best is here! Child & Adolescent Treatment Services and Lake Shore Behavioral Health are proud to become BestSelf Behavioral Health!